NCT03395197 2026-03-12
TALAPRO-2
Pfizer
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT04821622 2026-03-11
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer
Phase 3 Active not recruiting
NCT04991480 2026-01-27
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1 Completed
NCT04982848 2025-11-18
Korea Post Marketing Surveillance (PMS) Study of Talzenna®
Pfizer
Not yet recruiting
NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT03901469 2025-10-07
TNBC
Zenith Epigenetics
Phase 2 Terminated
NCT05059522 2025-06-25
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
Phase 3 Active not recruiting
NCT05650476 2025-06-12
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
Pfizer
Available